Vaccines for the prevention of infections with Bordetella
US9623102B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 25, 2014 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | Mar 25, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and/or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof.In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 μg per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.